Insulet Corporation PODD recently received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new ...

If you are wondering whether Insulet at around $304 a share is still a smart long term buy or if the easy money has already been made, you are not alone. Let's break down what the current price really ...

Insulet Corporation PODD recently made its Omnipod 5 Automated Insulin Delivery (“AID”) System commercially available in Australia. Omnipod 5 is available with Dexcom G6 and G7 continuous glucose ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received FDA 510(k) ...

Insulet Corporation (NASDAQ:PODD) shares are trading higher after the company reported preliminary second-quarter results. The company reported preliminary revenue of $488 million for the second ...

Insulet Corporation delivers strong fundamentals, with robust revenue growth, high margins, and impressive ROC. Learn more ...

Insulet recently announced that its Omnipod® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring System, enhancing its Automated Insulin Delivery capabilities. Over the ...

Omnipod 5 has been a major revenue catalyst for Insulet since its release. At the same time, operating expenses associated with Omnipod 5 are higher because of demand exceeding expectations. Higher ...

Insulet Corp. PODD announced that its Omnipod 5 Automated Insulin Delivery (“AID”) System is now compatible with Abbott’s ABT FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the ...